Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
30.04.08 - 21:25 ... source : Schering-Plough
... First batch of bluetongue Bovilis BTV8 vaccine released to supply Northern European countries BOXMEER, Netherlands, April 30 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health (NYSE: SGP) released the first batch of Bovilis BTV8 vaccine against bluetongue to supply in Northern Europe. The animal health company, combining after the acquisition in 2007 the strength of Intervet and Schering-Plough Animal Health, is not only the world market leader in the production of animal health vaccines, but also one of the world's leaders in the field of animal health. "Within the animal health sector, there has been a recent emphasis on prevention rather than treatment," says Ruurd Stolp, D.V.M., Ph.D., Senior Vice President and President Global Animal Health. "Our goal is to develop innovative vaccines that address unmet needs and improve disease protection as well as the duration of that protec ...» Next (HTML)
Similar news
89% | 24.04.08 - 00:48 ... source : Schering-Plough
... today announced two agreements to divest animal health products from 12 product franchises in Europe. These agreements are in connection with conditions set forth by the European Commission as part of its October 2007 clearance of Schering-Plough's acquisition of the ...
88% | 14.03.08 - 00:46 ... source : O'Reilly Media
... Book (No Starch Press) and contributor to The NXT STEP blog, found that most NXT enthusiasts were interested in creating big, bad robots, she decided to change things. "Everything seemed oriented toward adult techno-geeks and competition," she said. "It seemed ...
87% | 05.03.08 - 00:11 ... source : Citigroup
... the South Beirut – Citi and the Association for the Development of Rural Capacities (ADR) recently signed a grant agreement in support of vocational training for the micro and small enterprises (MSE's) in Lebanon. Provided by the Citi Foundation, Citi's ...
86% | 28.04.08 - 18:06 ... source : B. Braun
... "The Future of Sutures" competition initiated by B. Braun Melsungen AG has been taken up by many individuals and teams from all disciplines and from renowned university hospitals and institutes. Over 250 ideas have been submitted to the competition, which ...
86% | 25.04.08 - 11:25 ... source : GlaxoSmithKline
... April 2008, London, UK GlaxoSmithKline (GSK) announced today that the European Commission has issued marketing authorisation for Volibris® (ambrisentan) for the treatment of Pulmonary Arterial Hypertension (PAH) in patients classified as World Health Organisation (WHO) Functional Class II and III, ...
